We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · March 25, 2021

Post-Progression Outcomes of NSCLC Patients With PD-L1–High Expression Taking First-Line Single-Agent Pembrolizumab

European Journal of Cancer


Additional Info

European Journal of Cancer
Post-Progression Outcomes of NSCLC Patients With PD-L1 Expression ≥ 50% Receiving First-Line Single-Agent Pembrolizumab in a Large Multicentre Real-World Study
Eur. J. Cancer 2021 May 01;148(xx)24-35, A Cortellini, K Cannita, M Tiseo, DL Cortinovis, JGJV Aerts, C Baldessari, R Giusti, MG Ferrara, E D'Argento, F Grossi, A Guida, R Berardi, A Morabito, C Genova, L Antonuzzo, F Mazzoni, A De Toma, D Signorelli, A Gelibter, G Targato, F Rastelli, R Chiari, D Rocco, S Gori, M De Tursi, G Mansueto, F Zoratto, M Filetti, S Bracarda, F Citarella, R Marco, L Cantini, O Nigro, S Buti, G Minuti, L Landi, S Ricciardi, MR Migliorino, S Natalizio, C Simona, M De Filippis, G Metro, V Adamo, A Russo, GP Spinelli, M Di Maio, GL Banna, A Friedlaender, A Addeo, DJ Pinato, C Ficorella, G Porzio

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading